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Background: Superparamagnetic iron oxide nanoparticles have been used in clinical applications 
as a diagnostic contrasting agent. Previous studies showed that iron oxide nanoparticles deposited 
in the liver and spleen after systemic administration. The present study investigated the effect 
of iron oxide nanoparticles on antigen-specific immune responses in mice sensitized with the 
T cell-dependent antigen ovalbumin (OVA).
Methods: BALB/c mice were intravenously administered with a single dose of iron oxide 
nanoparticles (10−60 mg Fe/kg) 1 hour prior to OVA sensitization, and the serum antibody 
production and splenocyte reactivity were examined 7 days later.
Results: The serum levels of OVA-specific IgG1 and IgG2a were significantly attenuated by 
treatment with iron oxide nanoparticles. The production of interferon-γ and interleukin-4 by 
splenocytes re-stimulated with OVA in culture was robustly suppressed in mice administered 
with iron oxide nanoparticles. The viability of OVA-stimulated splenocytes was also attenuated. 
In contrast, treatment with iron oxide nanoparticles did not affect the viability of splenocytes 
stimulated with concanavalin A, a T-cell mitogen.
Conclusion: Collectively, these data indicate that systemic exposure to a single dose of iron 
oxide nanoparticles compromises subsequent antigen-specific immune reactions, including the 
serum production of antigen-specific antibodies, and the functionality of T cells.
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Introduction
Iron oxide nanoparticles have been used in various fields of biomedical research and 
clinical applications, including magnetic resonance imaging, cell labeling, cancer 
therapy and drug delivery.1–4 In particular, Resovist®, a preparation of carboxydextran-
coated superparamagnetic iron oxide nanoparticles, has been approved as a diagnostic 
contrast agent in many countries. Previous studies have shown that iron oxide nanopar-
ticles can be taken up by the reticuloendothelial system upon systemic administration, 
with the liver and spleen being the major organs of drug deposition.5–7 In addition, 
immune organs have been shown to be the main sites for the deposition of other nano-
particles following systemic exposure.8,9 Hence, the interaction between nanoparticles 
and immune cells and the consequences of such interactions are relevant issues in 
addressing the potential health impact of iron oxide and other nanoparticles.
The influence of iron oxide nanoparticles on macrophage functions has been 
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  suppress the phagocytic activity of Raw 264.7 cells, a murine 
macrophage line.10 Exposure of primary macrophages to 
iron oxide nanoparticles in culture resulted in a marked 
induction of oxidative stress and apoptosis.11 Furthermore, 
animal studies have shown that intratracheal instillation of 
mice with iron oxide nanoparticles induced a marked infiltra-
tion of inflammatory cells in the lungs and elevated levels 
of proinflammatory cytokines, including interleukin (IL)-1, 
IL-6 and tumor necrosis factor-α in the bronchoalveolar 
lavage fluid.12 These results clearly demonstrated that the 
functionality of macrophages was modulated by iron oxide 
nanoparticles upon in vitro and in vivo exposure. In   addition 
to macrophages, a recent study has shown that T cells were 
another target in the immune system sensitive to iron oxide 
nanoparticles. A single intravenous   administration of iron 
oxide nanoparticles to normal mice increased the number 
of both CD4+ and CD8+ cells in the peripheral blood, and 
the serum levels of IL-2 and interferon (IFN)-γ, two critical 
cytokines predominantly released by T cells.13 Together, 
these reports demonstrated that exposure to iron oxide 
nanoparticles affected some aspects of immune reactions 
mediated by macrophages and T cells. However, it is cur-
rently unclear if antigen-specific immunity is influenced by 
iron oxide nanoparticles.
In light of the available evidence showing the impacts of 
iron oxide nanoparticles on the functionality of macrophages 
and T cells, the objective of the present study was to investi-
gate the effect of iron oxide nanoparticles on antigen-specific 
immune responses in a murine model sensitized with oval-
bumin (OVA), a T cell-dependent antigen.14,15
Materials and methods
reagents and chemicals
All reagents were purchased from Sigma (St Louis, MO) 
unless otherwise stated. Enzyme-linked immunosorbent 
assay (ELISA) sets for cytokine measurement were   purchased 
from BD Biosciences (San Diego, CA). Fetal bovine serum 
(FBS) and cell culture supplies were purchased from Hyclone 
(Logan, UT). Resovist® (Schering AG, Berlin,   Germany), 
a commercial preparation of carboxydextran-coated iron 
oxide nanoparticles containing 28 mg Fe/mL, was used in 
the present study.
Animals
Male BALB/c mice (5 weeks old) were obtained from 
BioLasco (Ilan, Taiwan). On arrival, mice were randomly 
transferred to plastic cages containing aspen bedding and 
quarantined for at least 1 week. Mice were housed in a 
  temperature (22°C ± 2°C), humidity (50% ± 20%) and light 
(12-hour light/dark cycle)-controlled environment. Food and 
water were supplied ad libitum.
Animal experiment protocol
A previously described sensitization protocol was employed 
with minor modifications.16,17 Briefly, the mice were   randomly 
divided into the following groups (3–5   animals/group): naïve 
(NA), ovalbumin-sensitized (OVA), vehicle-treated and 
OVA-sensitized (VH), and iron oxide nanoparticle-treated and 
OVA-sensitized (Figure 1). Except for NA and OVA groups, 
the mice were administered intravenously with a   single 
dose of iron oxide nanoparticles (10, 30 and 60 mg Fe/kg; 
0.2 mL/mouse) and/or vehicle (VH; saline; 0.2 mL/mouse). 
Except for the NA group, the mice were sensitized 1 hour after 
drug administration with OVA by intraperitoneal injection 
using a sensitization solution   containing 100 µg OVA plus 
1 mg alum (as adjuvant) in saline (250 µL/mouse). The mice 
were sacrificed 7 days after OVA sensitization. Blood samples 
from individual mice were collected by cardiac puncture, and 
the serum was obtained by centrifugation of the coagulated 
blood at 3000 × g for 15 min. All animal experiments were 
approved by the Institutional Animal Care and Use Committee 
of the National Taiwan University.
Splenocyte culture
Spleens from the mice of the same group were aseptically 
isolated, pooled and made into single cell suspensions as 
described previously.18 Splenocytes were cultured in RPMI 
1640 medium supplemented with 100 U/mL penicillin, 
Day 0
1 h
NA:  Untreated, and not sensitized
OVA: Untreated, but sensitized
VH: Saline, 0.2 mL/mouse
Fe3O4 nanoparticles: 10–60 mg Fe/kg, 0.2 mL/mouse
Day 7
Treatment Sacrifice
OVA
sensitization
Figure 1 Protocol of iron oxide nanoparticle administration and OVA sensitization. 
BALB/c mice were randomly divided into the following groups (3–5 animals/group): 
naïve (NA), ovalbumin-sensitized (OVA), vehicle-treated and OVA-sensitized (Vh), 
and iron oxide nanoparticle-treated and OVA-sensitized. except for NA and OVA 
groups, the mice were administered intravenously with a single dose of iron oxide 
nanoparticles (10, 30 and 60 mg Fe/kg; 0.2 mL/mouse) and/or vehicle (Vh; saline; 
0.2 mL/mouse). except for the NA group, the mice were sensitized 1 hour after 
drug  administration  with  ovalbumin  (OVA)  by  intraperitoneal  injection  using  a 
sensitization solution containing 100 µg OVA plus 1 mg alum (as adjuvant) in saline 
(250 µL/mouse). Mice were sacrificed 7 days after OVA sensitization, and the spleen 
and blood were harvested for further experimentation.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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100 µg/mL streptomycin, and 10% heat inactivated FBS. In 
all cases, splenocytes were cultured at 37°C in 5% CO2.
Measurement of OVA-specific IgG by  
enzyme-linked immunosorbent  
assay (eLISA)
OVA-specific IgG1 and IgG2a were measured as previously 
described.19 In brief, ELISA plates were coated with 0.05% 
OVA in coating buffer (0.1 M NaHCO3), and blocked with 
1% bovine serum albumin in phosphate-buffered saline (PBS) 
containing 0.05% Tween20 (PBST). After washing with 
PBST, serum samples were placed into wells (50 µL/well) 
and incubated for 1 hour. After another washing, horse radish 
peroxidase-conjugated anti-mouse IgG1 and IgG2a was added 
(50 µL/well) and incubated for 1 hour. Lastly, wells were 
washed and a tetramethylbenzidine solution (50 µL/well) 
was added for colorimetric detection of bound peroxidase 
conjugate. The reaction was stopped by adding 150 µL per 
well of 3N H2SO4. The optical density (OD) was measured at 
450 nm using a microplate reader (Molecular Devices, Inc., 
Sunnyvale, CA). As the assay does not include a standard 
curve, the results are expressed as OD values.
Measurement of splenocyte viability
The viability of splenocytes was determined by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide 
(MTT) assay as previously described.20 Briefly, splenocytes 
(5 × 106 cells/mL) were cultured in triplicate (100 µL/well) 
in 96-well plates in the absence (no stimulation) or pres-
ence of OVA (50 µg/mL) for 72 hours or concanavalinA 
(ConA; 5 µg/mL) for 48 hours. An MTT stock solution 
(5 mg/mL in PBS) was added to each well (10 µL/well) and 
incubated for 4 hours. The formed formazan was then dis-
solved by adding 200 µL 0.1 N acid-isopropanol per well and 
shaken gently. OD was measured at 570 nm, and at 630 nm 
as a background reference, using a microplate reader.
cytokine measurement
The splenocytes (5 × 106 cells/mL) were cultured in qua-
druplicate in 48-well plates (0.25 ml/well), and stimulated 
with OVA (50 µg/mL) for 72 hours or ConA (5 µg/mL) for 
48 hours. The supernatants were collected and quantified for 
IL-4 and IFN-γ by ELISA as previously described.19
Flow cytometric analysis of splenocyte 
cellularity
Splenocytes obtained from each group were stained with rat 
anti-mouse CD4 conjugated with fluorescein isothiocyanate 
(FITC) and rat anti-mouse CD8 and B220 conjugated with 
PE-Cy5 antibodies (BioLegend, San Diego, CA) in PBS 
containing 2% fetal bovine serum (FBS). After washing, 
the single cell fluorescence of 10,000 cells for each sample 
was measured by a flow cytometer (BD FACSCalibur, San 
Jose, CA). Data were analyzed using the software Flowjo 
5.7 (Tree Star Inc, Ashland, OR).
Statistical analysis
The mean ± standard error (SE) was determined for each 
treatment group in the individual experiments. Homogeneous 
data were evaluated by a parametric analysis of variance, and 
Dunnett’s two-tailed t-test was used to compare treatment 
groups to the control group. P value , 0.05 was defined as 
statistical significance.
Results
exposure to a single dose of iron oxide  
nanoparticles attenuated antigen-specific  
antibody production
Mice were intravenously administered with a single dose 
of iron oxide nanoparticles (10−60 mg Fe/kg of body 
weight) and then sensitized with OVA (Figure 1). The 
doses were   chosen on the basis of previous studies using a 
similar range for magnetic resonance imaging of the liver 
and musculoskeletal infections in rats.21,22 To measure 
humoral responses, serum samples from individual mice 
were   collected 7 days after the OVA sensitization and 
OVA-specific antibodies were examined as   previously 
described.19 A marked increase in the serum levels of OVA-
specific IgG1 and IgG2a was observed in OVA-sensitized 
mice, as compared to non-sensitized naïve mice (Figure 2A 
and B; OVA   versus NA; P , 0.05), indicating a successful 
induction of humoral responses. No significant difference 
between the VH and OVA groups was observed (Figure 2A 
and B; VH versus OVA),   demonstrating that the VH 
treatment per se has no effect on the antibody responses. 
The production of OVA-  specific IgG1 was attenuated by 
the doses of 30 and 60 mg Fe/kg (Figure 2A; P , 0.05), 
whereas the low dose (10 mg Fe/kg) was   ineffective. These 
results showed a trend of dose-dependency by iron oxide 
nanoparticles on IgG1   production. Iron oxide nanoparticles 
(10−60 mg Fe/kg) also demonstrated a s  uppressive effect 
on the serum   production of OVA-specific IgG2a (Figure 2B; 
P , 0.05), in which the magnitude of suppression by all 
three doses was comparable, and no dose-dependency was 
observed.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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antigen-induced T cell reactivity
As T cells play a pivotal role in antigen-specific humoral 
responses, we examined the effect of iron oxide nanopar-
ticles on the functionality of T cells. Splenocytes isolated 
from naïve and OVA-sensitized mice were stimulated with 
OVA (50 µg/mL) in culture for 72 hours to induce antigen-
specific cytokine production. As expected, the amount of 
cytokines produced by splenocytes of the non-sensitized 
mice (NA) was very low, and the OVA stimulation markedly 
increased the production of IL-4 and IFN-γ by splenocytes 
of OVA-sensitized mice (Figure 3A and B; OVA versus 
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Figure 2 Attenuation by iron oxide nanoparticles of the serum production of OVA-specific IgG1 and Igg2a. Mice were treated with iron oxide nanoparticles and sensitized 
with OVA as depicted in Figure 1. The serum levels of OVA-specific IgG1 and Igg2a were measured by eLISA.
Note: Data are expressed as the mean ± Se of 9–15 samples pooled from 3 independent experiments. *P , 0.05 compared to the Vh group. 
Abbreviations: OVA, ovalbumin; eLISA, enzyme-linked immunosorbent assay; Se, standard error; Vh, vehicle treated group; OD, optical density.
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NA; P , 0.05). The production of IFN-γ was significantly 
suppressed in all iron oxide nanoparticle-treated groups with 
a comparable magnitude of inhibition between the 3 doses 
(Figure 3A; P , 0.05). The production of IL-4 was also 
markedly attenuated by the doses of 30 and 60 mg Fe/kg 
(Figure 3B; P , 0.05), whereas the low dose (10 mg Fe/kg) 
was ineffective. As the expression of antigen-induced cytok-
ines was suppressed by iron oxide nanoparticle treatment, the 
viability of splenocytes was further examined. As shown in 
Figure 4A, the viability of the OVA-stimulated splenocytes 
was attenuated in all three iron oxide nanoparticle-treated 
groups (P , 0.05). The cellularity of splenocytes was also 
Figure 3 Attenuation by iron oxide nanoparticles of antigen-induced production of IFN-γ and IL-4 by splenocytes. Mice were treated with iron oxide nanoparticles and 
sensitized with OVA as depicted in Figure 1. The splenocytes (5 × 106 cells/mL) isolated from each group of mice were re-stimulated with OVA (50 µg/mL) in culture for 
72 hours to induce cytokine production. The levels of (A) IFN-γ and (B) IL-4 in the supernatants were measured by eLISA.
Notes:  Data  are  expressed  as  the  mean  ±  Se  of  quadruplicate  cultures.  *P  ,  0.05  compared  to  the  Vh  control.  results  are  a  representative  of  3  independent 
experiments.
Abbreviations: OVA, ovalbumin; eLISA, enzyme-linked immunosorbent assay; Se, standard error; Vh, vehicle treated group.
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Table 1 exposure to iron oxide nanoparticles did not affect splenocyte cellularity
NA OVA VH Iron oxide nanoparticles (mg Fe/kg)
10 30 60
cD4+ (%) 25.4 ± 0.8 25.4 ± 1.1 24.8 ± 1.1 25.5 ± 0.6 24.5 ± 0.5 24.6 ± 0.6
cD8+ (%) 10.1 ± 0.5   9.1 ± 0.6   9.2 ± 0.5 10.0 ± 0.5   9.5 ± 0.8   8.6 ± 0.2
B220+ (%) 51.0 ± 1.0 46.1 ± 0.3 46.1 ± 1.0 47.3 ± 1.0 48.3 ± 0.6 47.8 ± 0.5
Notes: Splenocytes were prepared as described in the materials and methods. The percentage of cD4+, cD8+ and B220+ cells was determined by flow cytometry. The data 
are expressed as the mean ± Se of 3 experiments. 
Abbreviations: NA, naive; OVA, ovalbumin; Vh, vehicle.
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Figure 4 effect of iron oxide nanoparticles on the viability of splenocytes. Mice were treated with iron oxide nanoparticles and sensitized with OVA as depicted in Figure 1. 
The splenocytes (5 × 106 cells/mL) isolated from each group of mice were cultured in the absence or presence of OVA (50 µg/mL) for 72 hours or conA (5 µg/mL) for 
48 hours, and the viability of splenocytes was determined by an MTT assay.
Notes: Data are expressed as the mean ± Se of quadruplicate cultures. *P , 0.05 as compared with the matched Vh group. results are representative of 3 independent experiments.
Abbreviations: OVA, ovalbumin; conA, concanavalin A; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide; Se, standard error; Vh, vehicle treated 
group; OD, optical density.
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examined by flow cytometry, and no significant difference 
was observed in the percentage of splenic CD4+, CD8+ and 
B220+ cells among NA, VH- and iron oxide nanoparticle-
treated groups (Table 1). To further investigate the potential 
influence of iron oxide nanoparticles on T cell reactivity, 
splenocytes were stimulated with the T-cell mitogen ConA 
(5 µg/mL) for 48 hours and their viability was measured. 
Interestingly, the viability of ConA-stimulated splenocytes 
was not affected by treatment with iron oxide nanoparticles 
(Figure 4B).
Discussion
Nanotechnology has been increasingly applied in various 
fields, such as nanomedicine. A common application of 
nanomedicine is the clinical use of superparamagnetic iron 
oxide nanoparticles as contrast agents to enhance magnetic 
resonance imaging. Previous studies have shown that a 
considerable portion of systemically administered iron 
oxide nanoparticles is taken up by the   reticuloendothelial 
system leading to a potential exposure of immune cells to 
high   concentrations of the nanoparticles.5–7,23,24 Although 
a few studies demonstrated that iron oxide nanopar-
ticles affected the functionality of macrophages and 
lymphocytes,10,25,26   evidence pertaining to the influence of 
iron oxide   nanoparticles on antigen-specific immunity is 
scarce. In the present study, we investigated the in vivo 
effect of iron oxide nanoparticles on systemic antibody 
production and T cell responses in mice sensitized with 
OVA. Our data demonstrated that a single intravenous 
administration of iron oxide nanoparticles significantly 
attenuated the subsequent production of antigen-specific 
antibodies, as evidenced by a marked reduction in the 
serum levels of OVA-specific IgG1 and IgG2a (Figure 2). 
The viability and cytokine production by splenocytes 
  re-stimulated with the antigen OVA were also suppressed 
by iron oxide nanoparticles (Figures 3 and 4). In contrast, 
the viability of splenocytes stimulated with ConA, a T cell 
mitogen, was unaltered. Collectively, these results indicate 
that systemic exposure to a single dose of iron oxide nano-
particles differentially suppressed antigen-specific T cell International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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responses, in which the suppression of antigen-specific 
cytokine production may be attributed to a reduced viability 
of OVA-stimulated splenocytes.
T Helper (Th) cell-derived cytokines play a critical 
role in the activation and differentiation of B cells.27 In 
particular, the class switching from IgM to IgG2a and IgG1 
is dictated by Th1 (ie, IFN-γ) and Th2 (ie, IL-4) cytokines, 
respectively.27 In line with the attenuation of IgG2a and IgG1, 
both IFN-γ and IL-4 were suppressed in response to iron 
oxide nanoparticle exposure, suggesting that the attenu-
ated antibody production may be attributed to the changes 
in Th cell functions. This notion is further substantiated 
by our data showing that the viability of splenocytes re-
stimulated with the sensitized antigen OVA was attenuated 
by iron oxide nanoparticles. However, involvement of other 
immune cells cannot be ruled out. Antibody production is a 
complex process that requires interactions among various 
immune cells and the action of many mediators. Thus, in 
addition to T cells, other targets and/or mediators may be 
affected by iron oxide nanoparticles and contribute to the 
impaired humoral immunity. For   example, a recent study 
showed that the capability of dendritic cells to process 
antigen and stimulate T cell cytokine expression was sup-
pressed by exposure to iron oxide nanoparticles in vitro.28 
Since OVA is a T cell-dependent antigen that requires to 
be processed and presented by antigen-presenting cells,29 
we postulated that antigen presenting cells may be also 
involved in iron oxide nanoparticle-mediated attenuation 
of antibody production. This notion is indirectly supported 
by our data showing that the activation of splenocytes by 
ConA, whose responses are not antigen-specific, was not 
influenced by iron oxide nanoparticles. Further studies are 
required to determine whether the functionality of antigen-
presenting cells is modulated by iron oxide nanoparticles 
in vivo.
Resovist® has been used clinically as a liver-  specific 
  magnetic resonance (MR) contrast agent; for this 
  indication the recommended dose range is between 
0.42−0.65 mg Fe/kg in humans. Notably, a wider range 
of doses (0.14−22.4 mg Fe/kg) of Resovist® have been 
applied in rats for tracking MR signals in the liver.21 In 
addition to liver contrasting,   Resovist® at greater doses has 
been employed for imaging other tissues. For example, 
doses between 0.56−65 mg Fe/kg have been used to assess 
musculoskeletal infections in rats.22 Based on these lines of 
evidence, the dose range (10−60 mg/kg) used in our studies 
could be pharmacologically relevant for certain applications 
of iron oxide nanoparticles.
The production of IgG2a and IFN-γ, but not IgG1 and IL-4, 
was suppressed by the low dose of iron oxide nanoparticles 
(10 mg Fe/kg), whereas all the measured IgG and cytokines 
were attenuated by the higher doses (30 and 60 mg Fe/kg). 
These results suggest a differential sensitivity between Th1 
and Th2 responses to iron oxide nanoparticles, in which 
the Th1 immunity is slightly more sensitive to iron oxide 
nanoparticles. A previous report has shown that intratracheal 
administration of mice with iron oxide nanoparticles affected 
inflammation and T cell cytokine expression in the airways.25 
Given the pivotal role of Th cells in antigen-specific immu-
nity, systemic exposure to iron oxide nanoparticles may 
have a potential impact on the host immune responses to 
antigens. On one hand, iron oxide nanoparticle-mediated 
attenuation of T cell responses may be beneficial to people 
predisposed to allergy. On the other hand, the suppressed 
T cell immunity may be detrimental in situations where an 
appropriate immune response is necessary for the protection 
of the host.
Conclusion
The present study demonstrates that a single intravenous 
administration of iron oxide nanoparticles markedly sup-
presses T cell-mediated immune reactions with a broad 
spectrum covering both Th1- and Th2-type responses. We 
speculate that systemic exposure to iron oxide nanoparticles 
may have an impact on host immunity in response to specific 
antigens. On the base of these results, the immunomodula-
tory property of iron oxide nanoparticles warrants further 
and more comprehensive investigation.
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